Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
8.20
+0.36 (4.59%)
At close: Mar 4, 2026, 4:00 PM EST
8.12
-0.08 (-0.95%)
After-hours: Mar 4, 2026, 7:23 PM EST
Vanda Pharmaceuticals Revenue
In the year 2025, Vanda Pharmaceuticals had annual revenue of $216.11M with 8.72% growth. Vanda Pharmaceuticals had revenue of $57.22M in the quarter ending December 31, 2025, with 7.58% growth.
Revenue (ttm)
$216.11M
Revenue Growth
+8.72%
P/S Ratio
2.24
Revenue / Employee
$405,450
Employees
533
Market Cap
484.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 216.11M | 17.33M | 8.72% |
| Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
| Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
| Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
| Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
| Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
| Dec 31, 2019 | 227.19M | 34.07M | 17.64% |
| Dec 31, 2018 | 193.12M | 28.04M | 16.98% |
| Dec 31, 2017 | 165.08M | 19.07M | 13.06% |
| Dec 31, 2016 | 146.02M | 36.09M | 32.83% |
| Dec 31, 2015 | 109.93M | 59.77M | 119.16% |
| Dec 31, 2014 | 50.16M | 16.28M | 48.05% |
| Dec 31, 2013 | 33.88M | 1.15M | 3.52% |
| Dec 31, 2012 | 32.73M | 1.46M | 4.66% |
| Dec 31, 2011 | 31.27M | -4.44M | -12.43% |
| Dec 31, 2010 | 35.71M | 31.16M | 685.16% |
| Dec 31, 2009 | 4.55M | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 161.32M |
| Invivyd | 50.04M |
| Assembly Biosciences | 37.19M |
| Lineage Cell Therapeutics | 10.82M |
| Lyell Immunopharma | 41.00K |
VNDA News
- 1 day ago - Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - PRNewsWire
- 6 days ago - Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - PRNewsWire
- 7 days ago - Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug - Benzinga
- 7 days ago - Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire
- 9 days ago - Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy - Seeking Alpha
- 9 days ago - Vanda Pharmaceuticals stock's explosive rally may be more hype than substance - Invezz
- 9 days ago - Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment - Benzinga
- 12 days ago - US FDA approves Vanda's psychiatric drug - Reuters